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Localization of apolipoprotein(a) and B-100 in various renal diseases.
Recently it has become clear that abnormalities of lipid metabolism play
a large role in the progression of renal diseases. To investigate the
relationship between lipids and kidney tissue, we employed an immu-
nofluorescent technique to determine the localization pattern of apoli-
poprotein(a) [apo(a)], apoB-lOO, and low-density lipoprotein receptor in
the glomeruli, and analyzed the relationship between their presence and
the clinical and histological findings of a total 92 patients with glomer-
ular diseases. Immunostaining showed co-localization of apo(a) and
apoB-l00 in glomeruli. The patients were divided into three groups, as
follows: both apo(a) and apoB-100 positive (Group 1; 38 cases), apo(a)
positive only (Group 2; 19 cases) and apo(a) negative (Group 3; 35
cases). Group I had more severe proteinuria, higher levels of lipopro-
tein(a) [Lp(a)], and lower total protein levels than Group 3. Group 1 had
a higher prevalence of glomerulosclerosis and interstitial changes than
Group 3. Group 2 had more severe proteinuria and a higher prevalence
of glomerulosclerosis than Group 3. Although apo(a) and apoB-lOO are
almost absent in normal controls, these apoproteins [and presumably
lipoproteins Lp(a)j are present in the glomeruli of patients with glomer-
ular diseases. The data support the view that these apoproteins play a
significant role in progressive renal diseases.
Hyperlipidemia and hypercholesterolemia are thought to
contribute to the pathogenesis of progressive renal disease in
several animal models. Diamond described focal segmental
sclerosis as an analogue of atherosclerosis [1]. It may also play
an important role in the progression of human glomerular
diseases [2]. We recently reported that apoB and apoE are
deposited in glomeruli in the setting of renal disease, and
showed that the deposition of these apolipoproteins might
accelerate the progression of renal disease [3].
Evidence that lipoprotein(a) [Lp(a)] and low-density lipopro-
tein (LDL) are similarly atherogenic has been obtained by the
localization of both proteins in atheromatous arteries and vein
grafts [4]. The structure, metabolism, and epidemiology of
Lp(a) have recently been reviewed in detail [5], It is now known
that apolipoprotein(a) [apo(a)I, a glycoprotein that is present in
Lp(a) and covalently linked to apolipoprotein B-100 (apoB-100),
the principal apolipoprotein of LDL, has close structural ho-
mology with plasminogen, both gene loci being closely linked
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on the long arm of chromosome 6. This finding has led to the
suggestion that Lp(a) may have thrombogenic as well as athero-
genic properties.
The present study was undertaken to determine the presence
of apo(a), apoB-l00, and LDL receptor (LDLR) in renal biopsy
specimens by an immunofluorescent technique and to clarify
the relationships between the presence of apo(a) and apoB-100
and clinical and histological features.
Methods
Ninety-two patients (49 males, 43 females) with various renal
diseases who were admitted and examined by renal biopsy in
Niigata University Hospital (34 patients) and its affiliated hos-
pitals (58 patients) between February and July 1991 served as
the study group. Patient ages ranged from 9 to 76 years;
duration from onset of urinary abnormalities until renal biopsy
ranged from 1 month to 26 years. Kidney tissue specimens were
obtained from these patients by percutaneous renal biopsy. The
relationship between the apolipoprotein staining pattern and
clinical or histological features was examined in all subjects.
Serum Lp(a) was examined in the 34 patients who were at
Niigata University Hospital (4 had minor glomerular abnormal-
ities, 12 had IgA nephropathy, 5 had non-IgA nephropathy, 3
had membranous nephropathy, 2 had membranoproliferative
glomerulonephritis, 2 had minimal change nephrotic syndrome,
1 had benign nephrosclerosis, 2 had lupus nephritis, 1 had
polyarthritis nodosa, 1 had reflux nephropathy, and 1 had
Wegener's granulomatosis). Serum Lp(a) levels ranged from 1.1
mg/dl to 170.8 mg/dl.
In the immunofluorescent microscopy cases, a small piece of
a specimen was embedded in OCT (Miles Scientic, Naperville,
Illinois, USA) and quickly frozen in dry ice and acetone at
—70°C. Cryostat sections were cut 2 to 3 microns thick, and
rinsed in phosphate-buffered isotonic saline (PBS, pH 7.2) three
times for 15 minutes. Fibrinogen was stained by a direct
immunofluorescent method as follows: the sections were incu-
bated with FITC conjugated polyclonal anti-human fibrinogen
antibody (Behringer, Germany) for 30 minutes at room temper-
ature, and rinsed three times in PBS for 15 minutes mounted in
glycerin. Apo(a), apoB-lOO, and LDLR were stained by an
indirect immunofluorescent method. After being covered with
mouse monoclonal anti-human apo(a) (Cappel, USA), mouse
monoclonal anti-cow LDLR antibody (Amersham, USA), and
mouse monoclonal anti-human apoB- 100 antibody (JIMRO,
430
Sato et a!: Apo(a) and apoB-100 in glomeruli 431
Japan), the sections of apo(a) were incubated for 30 minutes at
room temperature, and the sections of apoB-100 and LDLR
were incubated overnight at 4°C. After washing three times in
PBS for 15 minutes, they were incubated for 30 minutes with
fluorescein-conjugated rabbit anti-mouse immunoglobulin anti-
sera (DAKO, Denmark), which was preadsorbed in normal
human serum. Sections were again washed three times in PBS,
mounted in glycerin and observed under a Zeiss Axiophot
fluorescent photomicroscope. The specificity of apo(a) antibody
was confirmed by Western blot analysis, and there was no cross
reactivity with LDL or plasminogen. There was no different
staining between the antibody adsorbed with plasminogen prior
to the immunofluorescence staining and non-adsorbed anti-
body. The anti-LDLR may recognize the cell surface or inter-
nalized LDLRs [6]. The anti-cow LDLR antibodies are known
to cross react with human LDLR [7]. The specificities of
apoB-100 and LDLR antibody were confirmed by Western blot
analysis, and no cross reactivity was found with other apoli-
poproteins. The patients were divided into three groups on the
basis of immunofluorescent microscopic staining pattern find-
ings of apo(a) and apoB-100 as follows: both apo(a) and
apoB- 100 positive (Group 1; 38 cases), apo(a) positive only
(Group 2; 19 cases), and apo(a) negative (Group 3; 35 cases).
In the light microscopic study cases, renal biopsy specimens
were fixed in 50% alcohol-Bouin's mixture (saturated picric
acid in 50% ethanol, 40 ml; 35% formalin, 7.5 ml; acetic acid,
2.5 ml), embedded in paraffin, and cut into sections 2 to 3
microns thick. The sections, stained with hematoxylin-eosin,
periodic acid Schiff, and periodic acid-methenamine silver
stain, were examined under a Zeiss Axiophot light microscope.
The mesangial lesion, an increase in cells and/or matrix, was
divided into focal and diffuse proliferation. The presence of
glomerular adhesions, sclerosis, vascular changes, and intersti-
tial changes was also evaluated. Serum samples were obtained
from the patients after 12 hours of fasting. Total cholesterol
(TC), triglyceride (TG), uric acid (UA), and total protein (TP)
were determined via standard laboratory methods. Lp(a) was
determined using an ELISA method [TintElize Lp(a), Biopool,
UmeA, Sweden]. Urinary protein excretion (Un) and creatinine
clearance (Car) were calculated from 24-hour urine samples.
Statistical analysis was performed using the chi-square test,
or Wilcoxon's U-test. A probability of P < 0.05 was regarded as
significant.
Results
Apo(a), apoB-100, and LDLR were demonstrated to have a
granular pattern in the glomeruli, mainly in the mesangial area
and occasionally along capillary loops, as shown in Figure 1. In
two control tissue specimens from patients with non-tumorous
renal cell carcinoma, two cases of Bartter's syndrome, three
cases of thin basement membrane disease (TBD), no apo(a),
apoB-lOO, or LDLR were detected in the glomeruli. These
controls had normal renal function, no glomerular and intersti-
tial injury, and no proteinuria; three cases of TBD only had
microscopic hematuria. Among the patients with primary gb-
merulonephritis, 6 had minor glomerular abnormalities, 39 had
IgA nephropathy (IgAGN), 9 had non-IgAGN, 7 had membra-
nous nephropathy, 2 had membranoproliferative glomerulone-
phritis, 6 had minimal change nephrotic syndrome, 1 had
endocapillary proliferative glomerulonephritis, and 2 had be-
Fig. 1. A. Apo(a) deposition in glo,neruli. B. ApoB-l00 deposition in
gbomeruli. C. LDL receptor in glomeruli. Immunohistochemistry was
performed with monocbonal anti-apo(a) and anti-apoB-100. For detec-
tion, an indirect immunofluorescent method was used. (Original mag-
nification x400; IgA nephropathy).
nign nephrosclerosis. Among those with secondary glomerular
diseases, 8 had diabetic glomerubosclerosis, 7 had lupus nephri-
tis, 2 had Henoch-Schonlein purpura nephritis, 1 had poly-
arthritis nodosa, 1 had reflux nephropathy, and 1 had Wegen-
er's granulomatosis, as shown in Table 1. The relationship
between apolipoprotein staining and histological findings is
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Table 1. Histological diagnosis and number of patients in each Group
(total: 92)
Group 1 Group 2 Group 3
number
Primary glomerular diseases
MGA 2 1 3
IgAGN 15 10 14
nonigAGN 3 0 6
MN 4 0 3
MPGN 1 0 1
MCNS 2 3 1
EndocapPGN I 0 0
Nephrosclerosis 0 1 1
Secondary glomerular diseases
DMGS 4 2 2
SLE 2 1 4
HSPG 2 0 0
PN 1 0 0
RF 1 0 0
WG 0 1 0
Abbreviations are: MGA, minor glomerular abnormalities; IgAGN,
IgA nephropathy; MN, membranous nephropathy; MPGN, membran-
oproliferative glomerulonephritis; MCNS, minimal change nephrotic
syndrome; EndocapPGN, endocapillary proliferative glomerulonephri-
tis; Nephrosclerosis, benign nephrosclerosis; HSPG, Henoch-Shonlein
purpura nephritis; PN, polyarthritis nodosa; DMGS, diabetic glomeru-
losclerosis; SLE, lupus nephntis; RF, reflux nephropathy; WG, We-
gener' s granulomatosis.
shown in Table 2. Glomerulosclerosis was observed in 70% of
Group 1 patients, in 68% of Group 2, and in 32% of Group 3.
Significant differences were found between Groups 1 and 3, and
between Groups 2 and 3 (P < 0.01 and P < 0.05, respectively).
Interstitial scarring was present in 75% of Group 1 patients, in
68% of Group 2, and in 44% of Group 3. There was a significant
difference between Groups 1 and 3 (P < 0.01). There was no
relationship between glomerular apolipoprotein staining and
fibrinogen deposition in glomeruli or other histological findings.
Table 3 shows the relationship between apo(a) and apoB-100
and clinical features. UP in Group 1, 2.6 5.0 glday, and in
Group 2, 2.9 3.9 glday, was significantly greater than in
Group 3,0.9 1,4 glday (P <0.01 and P < 0.05, respectively).
TP in Group 1 (6.2 0.9 g/dl) was significantly lower than in
Group 3 (7.0 0.7 g/dl; P < 0.01). The serum level of Lp(a) in
Group I (N = 15; 47.8 43.3 mgldl) was significantly higher
than in Group 3 (N = 14; 13.2 9.5 mgldl; P < 0.01). There
were no significant differences in age, Cc, UA, TC, TG, or
disease duration among the three groups.
As shown in Figure 2, LDLR was detected in 63% (24 of 38)
of Group 1 patients. In Group 2, LDLR was detected in 15% (3
of 19) and in Group 3 in 20% (7 of 35). Apo(a) and apoB-100
were co-localized in glomeruli mainly in the mesangial area and
occasionally in capillary ioops.
There was a significant relationship between LDLR staining
and proteinuria; LDLR positive cases had more severe protein-
uria than negative cases (2.9 5.5 g/day vs. 1.7 2.9 g/day; P
< 0.05). However, there was no significant relationship be-
tween LDLR staining and TC [259.4 111.9 mg/dl (LDLR
positive) vs. 207.2 71.3 mg/dl (LDLR negative); P < 0.1].
Discussion
Both Lp(a) and apo(a) compete with plasminogen for binding
to endothelial plasminogen receptors [8, 9]. The binding of
plasminogen to receptor at the endothelial layer of blood
vessels is thought to facilitate the interconversion of plasmino-
gen to active protease plasmin. Lp(a) and apo(a) inhibit the
tissue plasminogen activator-mediated activation of plasmino-
gen. Another feature of Lp(a) is its ability to bind to proteolyt-
ically degraded fibrin [10]. Therefore, Lp(a) may interfere with
an essential step in fibrinolysis and hence modulate the clotting
process. Glomerular fibrin deposition is a prominent feature of
the coagulation abnormalities in aggressive proliferative gb-
merulonephritis, and is considered to be one factor leading to
clinical progression [11]. Apo(a) deposition in glomeruli might
affect the coagulation system, thereby mediating the progres-
sion of renal damage. However, there was no relationship
between apo(a) and fibrinogen deposition in glomeruli, since
anti-fibrinogen antibody utilized in this study recognizes fibrin-
ogen and other breakdown products of fibrinogen, but does not
recognize fibrin.
Groups I and 2 had more sclerotic glomeruli and tubuloin-
terstitial changes than Group 3. Lp(a) is able to bind fibronectin
[121, which is detected much more commonly in the mesangial
proliferative region than the nonproliferative region of glomer-
uli [13]. Lp(a) present in glomeruli might reflect a larger amount
of fibronectin than if Lp(a) were absent in glomeruli. It can be
expected that an increase in the synthesis or a disturbance in
the degradation of fibronectin would cause the expansion of
extracellular matrix, glomeruboscierosis, and interstitial
changes.
Recently, Lp(a) has been shown to inhibit the generation of
transforming growth factor beta (TGF-f3). Lp(a) might inhibit
the activation of latent TGF-f3 by competing with the binding of
plasminogen to cell or matrix surfaces [14]. TGF-f31 is now
recognized to be a multifunctional cytokine with both growth
promoting and growth inhibiting activities in various cell types.
TGF-/ acted as an inhibitory regulator of mesangial cell prolif-
eration. On the other hand, TGF-p promotes mesangial cells to
produce mesangial matrix, that is, collagen, fibronectin, and
laminin [15]. TGF-f31 was produced by smooth muscle cells
during repairing of artery injury [16]. Therefore, apo(a) depos-
ited in the mesangial area may interfere with repairing injured
cells or tissue.
Proteinuria is a key feature of progressive renal diseases,
often being used as a parameter of the effect of treatment or
experimental manipulations. There is a strong relation between
proteinuria and plasma cholesterol concentration [17]. There
have only been a few reports on proteinuria and serum Lp(a)
concentrations [18, 19]. In this study, we demonstrated that
apo(a) and apoB-lOO accumulate in glomeruli in the setting of
various renal diseases. We also showed that apo(a) and apoB-
100 co-localized in glomeruli. This indicates localization of
lipoprotein-like particles in glomeruli, since both apoproteins
are present in Lp(a), usually as a disulfide-linked complex. That
both apo(a) and apoB-100 are immunologically detectable in
glomeruli suggests that major Lp(a) components accumulate
extracellularly instead of being digested within cells. But in
Group 2, which comprised only 20% of all our cases, apo(a)
alone was deposited in gbomeruli. These findings suggest that
Lp(a) might be degraded in gbomeruli. However, apo(a) and
apoB-100 could be subject to alterations related to the tissue
preparation process that would render their antigenic determi-
nants unavailable for binding with the antibody, and in addition,
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Table 2. Relationship between glomerular apolipoprotein deposition and histological findings
Group I(N = 38)
Group 2(N = 19)
Group 3(N = 35) Statistical significance
Diffuse mesangial cell proliferation 35% 42% 21% NS
Diffuse mesangial matrix proliferation 62% 68% 54% NS









< 0.01 (Group I vs. Group 3)
P < 0.05 (Group 2 vs. Group 3)
NS
Interstitial changes 75% 68% 44% P < 0.01 (Group 1 vs. Group 3)
Fibrinogen deposits 32% 23% 20% NS
Groups 1 and 2 had more sclerotic glomeruli and tubulointerstitial scarring than Group 3. There was no relationship between apo(a) and apoB-lOO
and other histological findings. NS, not significant.
Group I(N = 38)
Group 2(N = 19)
Group 3(N = 35)
Age years 38.8 16.3 43.2 20.9 38.3 15.2
Proteinuriag/day 2.6 5.oa 2.9 39b 0.9 1.4
Ccr mI/mm 80.0 36.5 81.4 26.2 95.2 36.3
UA mg/dl 5.9 1.8 5.5 1.1 5.2 1.8
TP g/dl 6.2 0.9k 6.5 0.9 7.0 0.7
TC mg/dl 243.4 106.1 205.9 72.5 201.6 64.3
TG mg/dl 156.2 110.0 209.7 185.4 122.7 84.3
Lp(a) mg/dl 47.8 433a(N = 15)
29.6 32.9(N = 5)
13.2 9.5
(N = 14)
Disease duration 5.6 6.5 6.2 9.1 4.2 6.2
years
Abbreviations are: Car, creatinine clearance; UA, uric acid; TP, total
protein; TC, total cholesterol; TG, triglyceride; Lp(a), lipoprotein(a);
NS, not significant. U, in Groups 1 and 2 was significantly greater than
in Group 3. UA in Group 1 was significantly higher than in Group 3. TP
in Group 1 and 2 was significantly lower than in Group 3. The serum
level of Lp(a) in Group I was significantly higher than in Group 3.
P < 0.01 compared with Group 3
b P < 0.05 compared with Group 3
the clinical parameters in Group 2 are similar to those in Group
1. Therefore, it cannot be said with certainty that apoB-100 is
not present in Group 2. This study involved the use of a mouse
monoclonal anti-human apo(a) antibody, and it might not detect
all apo(a) isoforms [5, 20, 211; therefore, it is possible that the
apo(a) negative group could actually have apo(a) present with
different antigenic determinants not recognized by the mono-
clonal antibody used. Serum levels of Lp(a) in Group 1 were
higher than in Group 3. Proteinuria in Group 1 was greater than
in Group 3. These findings suggest that proteinuria affects the
serum Lp(a) concentration, and that Lp(a) might deposit in
glomeruli. The mechanism of apo(a) deposition in glomeruli is
unknown. However, some mechanisms have been postulated.
The site and mechanism of Lp(a) catabolism is still under
debate, but the LDL receptor pathway seems to be emerging as
a major route [22]. First, LDLR was shown in glomeruli in 63%
of Group 1 patients, but only in 15% of Group 2 and 20% of
Group 3. These findings suggest that some apo(a) bound with
apoB-100, while the remaining apo(a) without apoB-100 might
enter glomeruli via LDLRs, since mesangial and epithelial cells
possess LDLRs [23, 24]. In this study, LDLR positive cases
had more severe proteinuria than negative cases, but there was





LDL pathway functions to maintian a constant concentration of
cellular cholesterol. Additionally, it is suggested that arachi-
donic acid obtains access to cells via LDLR; therefore, pros-
taglandin formation is directly linked to this pathway [25].
LDLR present in glomeruli might somewhat relate to arachido-
nate metabolism. In the kidney, eicosanoids are involved in the
regulation of renal vascular tone and tubular function under
normal conditions, and in mediating alternations in glomerular
function during injury [261. Moreover, overexpression of LDLR
in glomerular diseases might lead to accelerated catabolism of
Lp(a) [22]. Second, although scavenger receptors were not
revealed in glomeruli, the cases without the present of LDLR in
Groups 1 and 2 might enter glomeruli via scavenger receptors.
Mouse macrophages take up recombinant apo(a) via scavenger
receptors and degradation of apo(a) [27]. Third, serum Lp(a) is
trapped in glomeruli, and apo(a) might bind to fibronectin or
glycosaminoglycans around the mesangium [12]. Michael et al
described that the mesangium has a pathway to remove mac-
romolecules from the mesangial zone to the hilum of the
glomerulus [281. Local intraglomerular hemodynamic changes
may modulate uptake and disposal of macromolecules, Lp(a),
and Lp(a) was present in mesangium. However, this trapped
Lp(a) could then be subject to oxidative modification, espe-
cially under conditions of local activation of mesangial cells and
monocytes. Oxidized Lp(a) has the potential to be pathologi-
cally significant, which leads to its uptake by macrophages [29].
Table 3. Relationship between glomerular apolipoprotein deposition





apo(a) (+) (+) (+) (+) (—) (—) (—) (—)
apoB—1 00 (+) (+) (—) (—) (+) (+) (—) (—)
LDL receptor (+) (—) (+) (—) (+) (—) (+) (—)
Fig. 2. Relationship between apo(a), apoB-100 and LDL receptor
staining in glomeruli.
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The major site of apo(a) synthesis is the liver, and small
amounts of mRNA have also been detected in brain and testis
[301, but there have been no reports of Lp(a) production in the
kidney, However, it is unknown whether apo(a) synthesis might
occur in glomeruli in various renal disease states.
Serum and liver samples from various specimens were ana-
lyzed for the presence of Lp(a), but only humans, primates, and
hedgehogs were found to express apo(a) [31, 32]. The rat and
the mouse, the most common animal models available for
experimentation, do not express apo(a). Treatment of hyperlip-
idemia by a 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitor in the obese Zucker rat [331, or by clofibric acid in the
rat 5/6 nephrectomy model, reduces glomerular injury [34].
Although there has been one report of reduced renal injury [35],
lipid lowering agents in human renal diseases do not always
ameliorate renal damage. These findings suggest that Lp(a)
might have some effects on human renal diseases, in contrast to
experimental animal models.
Lp(a) is a qualitative and quantitative genetic trait. Around
70% of normal people have serum Lp(a) levels below 25 mg/dl.
Utermann has postulated that there is a highly significant
association between the Lp(a) concentration in serum and the
different apo(a) phenotypes on SDS-PAGE. It is estimated that
only 40% of the plasma level of Lp(a) is under the control of the
apo(a) gene, indicating that more than half of the Lp(a) level is
determined by the action of other genes and/or environmental
factors [5]. However, in renal diseases, serum Lp(a) might
change according to proteinuria. For example, 10 mg/dl of
serum Lp(a) without proteinuria might increase to 20 mg/dl
when proteinuria is overt, and Lp(a) might then deposit in
glomeruli. Therefore, it might be prudent to recommend de-
creasing serum Lp(a) levels in renal diseases. Whether the
lowering of high Lp(a) plasma levels beneficially influences the
progression of renal diseases is unknown.
In conclusion, this is the first study showing a significant
relationship between Lp(a) serum levels and apo(a) and apoB-
100 presence in glomeruli. Our studies imply that Lp(a) enters
the mesangial area and capillary loops, where co-localization of
apo(a) and apoB-l00 can be shown by immunohistochemical
methods. Lp(a) hyperlipidemia and apo(a) deposition in glomer-
nh may participate in the persistence and progression of renal
damage in all types of immunologically and nonimmunologi-
cally mediated renal diseases. More detailed studies will be
required to evaluate the present data and to finally elucidate the
role of Lp(a) in renal diseases.
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